Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
暂无分享,去创建一个
Nicholas Bruchovsky | N. Bruchovsky | J. Crook | L. Klotz | Juanita Crook | S. Larry Goldenberg | Laurence Klotz | S. Goldenberg
[1] Nicholas Bruchovsky,et al. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer , 2006, Cancer.
[2] T. Pickles. Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. , 2006, International journal of radiation oncology, biology, physics.
[3] J. Crook,et al. Should intermittent androgen deprivation be used in routine clinical practice? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] G. Perry,et al. Long‐term side‐effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study , 2005, BJU international.
[5] S. Steinberg,et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. , 2005, The Journal of urology.
[6] Mohammad H. Rashid,et al. Intermittent androgen deprivation therapy for prostate cancer. , 2004, The oncologist.
[7] L. Collette,et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. , 2003, European urology.
[8] M. Gleave,et al. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience. , 2003, The Canadian journal of urology.
[9] B. Escudier,et al. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. , 2003, European urology.
[10] M. Gleave,et al. A meaningful legacy: urologists as Nobel Prize laureates. , 2003, The Canadian journal of urology.
[11] M. Benson,et al. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. , 2000, The Journal of urology.
[12] Crawford,et al. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials , 2000, The Lancet.
[13] N. Bruchovsky,et al. Prostate cancer: molecular biology of early progression to androgen independence. , 1999, Endocrine-related cancer.
[14] D. Grignon,et al. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. , 1998, Urology.
[15] S. Goldenberg,et al. Effects of intermittent androgen suppression on androgen‐dependent tumors. Apoptosis and serum prostate‐specific antigen , 1993, Cancer.
[16] W. Bremner,et al. Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. , 1989, Journal of andrology.